Analysts Remain Bullish Despite Biomea Fusion’s Stock Volatility Biomea Fusion’s stock has faced sharp declines, hitting a 52-week low, yet analysts maintain a consensus "Buy" rating with average price targets far above current trading levels. The company’s liquidity remains solid, and its lead diabetes drug, icovamenib, continues to show promise in clinical studies, supporting optimism for a turnaround.4567